Compare Dover Corp (DOV) vs Moderna, Inc. (MRNA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Dover Corp vs Moderna, Inc. — how do they compare? Dover Corp trades at $208.53 (market cap $28.07B), while Moderna, Inc. trades at $64.05 (market cap $24.18B). The key difference: Dover Corp is the larger of the two by market cap, and Dover Corp pays a 1.01% dividend while Moderna, Inc. pays none. Which is the better fit depends on your goals.
| DOV | MRNA | |
|---|---|---|
Market Cap | $28.07B | $24.18B |
Sector | Industrials | Health |
52-Week High | $233.31 | $81.80 |
52-Week Low | $161.16 | $22.36 |
Enterprise Value | $29.58B | $20.33B |
Dividend Yield | 1.01% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DOV trades at $207.92, down 1.04% on the day, with a bearish technical signal despite strong fundamentals. The company has beaten EPS estimates for three consecutive quarters, maintains a 13.48% net income margin, and recently raised its dividend. Analyst consensus is strongly bullish with a $232.33 price target. Recent news highlights manufacturing strength and strategic acquisitions like Cloeren, supporting growth in data center and AI segments.
The outlook is positive given earnings momentum, dividend growth, and raised 2026 guidance. Risks include market volatility and execution of acquisitions. With no sell ratings and solid cash flow, DOV offers a balanced opportunity for growth and income, though technical indicators suggest near-term caution.
Moderna (MRNA) trades at $63.57, up 6.29% on the day, reflecting positive momentum following FDA approval of its mRNA flu vaccine, mFLUSIVA, for adults 50 and older. The stock exhibits a bullish technical outlook with moving averages supporting upward movement, though RSI levels suggest potential overbought conditions. Fundamentally, revenue has declined from pandemic peaks, with 2025 revenue at $1.92B and a net loss of -$2.82B, yet the company has beaten EPS estimates in recent quarters. Cash flow trends show improvement, with net cash flow turning positive in 2025 at $668M.
The outlook for MRNA hinges on pipeline execution beyond COVID-19, with recent vaccine approvals providing growth catalysts. Investment opportunities include diversification into flu, Ebola, and oncology therapies, but risks persist from high cash burn, competitive pressures, and reliance on successful clinical trials. Analyst sentiment is mixed with a consensus price target of $54.33, below the current price, indicating caution despite some bullish developments.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Dover Corp
Dover is a diversified industrial manufacturing company with products and services that include digital printing for fast-moving consuming goods, marking and coding for the food and beverage industry, loaders for the waste collection industry, pumps for the transport of fluids, including petroleum and natural gas, and commercial refrigerators used in groceries and convenience stores. Most of the business operates in the United States. After the spinoff of Apergy, the company operates through five segments: engineered systems, clean energy and fueling solutions, imaging and identification, pumps and process solutions, and climate and sustainability technologies equipment.
Read more on DOV →About Moderna, Inc.
Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.
Read more on MRNA →
